Pheon Therapeutics
26 employees
Biotech/Pharma
Series B · $188.0M
Open positions (2)
Company details
Team Size26
IndustryBiotech/Pharma
Funding
Total raised
$188.0M
Last stage
Series B
Investors
Brandon Capital
Total raised
$188.0M
Last stage
Series B
Investors
Bertrand Damour
Headed Pheon at launch with 20+ years of biotech management experience. Previously CEO of NBE Therapeutics (acquired by Boehringer Ingelheim for $1.4B in 2020), GeneProt, Mind NRG, and OncoEthix.
David Thurston
Emeritus Professor of Drug Discovery; previously co-founded Spirogen, whose payload technology underpins the approved ADC Zynlonta. Academic origin of the King's College London spinout that became Pheon Therapeutics.
Paul Jackson
Co-founded Pheon Therapeutics (formerly Femtogenix) in 2015. Earned his PhD in Prof. David Thurston's lab at King's College London, developing ADC payload design methods. Led R&D and business development from the company's foundation.
LinkedInNo applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.